Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors
about
Effects of mutant p53 expression on human 15-lipoxygenase-promoter activity and murine 12/15-lipoxygenase gene expression: evidence that 15-lipoxygenase is a mutator geneA proinflammatory cytokine inhibits p53 tumor suppressor activityInduction of apoptosis by cytoplasmically localized wild-type p53 and the S121F mutant super p53Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3betaThe p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/MInhibition of nuclear import by protein kinase B (Akt) regulates the subcellular distribution and activity of the forkhead transcription factor AFX.MDMX: a novel p53-binding protein with some functional properties of MDM2Cell Proliferation in NeuroblastomaReactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumorsClinical utility of anti-p53 auto-antibody: systematic review and focus on colorectal cancerCDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma CellsAtomic Structure of Dual-Specificity Phosphatase 26, a Novel p53 PhosphataseA role for Hsc70 in regulating nucleocytoplasmic transport of a temperature-sensitive p53 (p53Val-135)Aberrant p53 expression in feline vaccine-associated sarcomas and correlation with prognosisA monoclonal antibody against p53 cross-reacts with processing bodiesRegulation of p53 by Mdm2 E3 ligase function is dispensable in embryogenesis and development, but essential in response to DNA damageP53 is transported into the nucleus via an Hsf1-dependent nuclear localization mechanismChromosomal mapping and expression of the human cyr61 gene in tumour cells from the nervous systemThe subcellular localization of IGFBP5 affects its cell growth and migration functions in breast cancer.The emerging p53 gene family.Characterization of novel and uncharacterized p53 SNPs in the Chinese population--intron 2 SNP co-segregates with the common codon 72 polymorphismp53 regulation by post-translational modification and nuclear retention in response to diverse stresses.Genetic evidence of a role for ATM in functional interaction between human T-cell leukemia virus type 1 Tax and p53.Impaired p53 binding to importin: a novel mechanism of cytoplasmic sequestration identified in oxaliplatin-resistant cells.Nucleo-cytoplasmic shuttling of the hdm2 oncoprotein regulates the levels of the p53 protein via a pathway used by the human immunodeficiency virus rev protein.A leucine-rich nuclear export signal in the p53 tetramerization domain: regulation of subcellular localization and p53 activity by NES masking.Induction of p53-mediated transcription and apoptosis by exportin-1 (XPO1) inhibition in mantle cell lymphoma.Inactivation of p53 by human T-cell lymphotropic virus type 1 Tax requires activation of the NF-kappaB pathway and is dependent on p53 phosphorylation.MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification.Dial 9-1-1 for p53: mechanisms of p53 activation by cellular stressProtein mislocalization: mechanisms, functions and clinical applications in cancer.Microtubule-dependent subcellular redistribution of the transcriptional coactivator p/CIP.Nuclear-cytoplasmic shuttling of the oncogenic mouse UNP/USP4 deubiquitylating enzyme.Targeting nucleocytoplasmic transport in cancer therapyNucleo-cytoplasmic transport as a therapeutic target of cancerNuclear and cytoplasmic p53 suppress cell invasion by inhibiting respiratory complex-I activity via Bcl-2 family proteins.Early growth response 3 (Egr3) is highly over-expressed in non-relapsing prostate cancer but not in relapsing prostate cancerCyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma.Assessing TP53 status in human tumours to evaluate clinical outcome.Actin polymerization negatively regulates p53 function by impairing its nuclear import in response to DNA damage.
P2860
Q22009375-35BAB66E-1FA3-497C-A1D0-AA78937D55D3Q22010796-7D402EC9-D737-404D-A22C-B963946F33CBQ24293008-5CD4D19C-31B1-46E8-8A92-5ACA828A0847Q24306430-4C3ACEDE-D73E-4E4A-8DDE-A6A226D502AEQ24323137-A6063BA9-15CD-49FE-8F60-69222E3B715CQ24514761-28624FCD-E6C4-46C7-BCB2-854770946583Q24561971-C4CF28C5-035C-485D-845E-0F47D4C11F06Q26771708-6285A76F-79EE-4CBD-92D3-4EA579A0507CQ26783710-157B5D8D-40B0-4A83-BD1D-868C8ADE9657Q27002356-FD988AA1-4C7B-49E5-AD53-4C4361F7D871Q27670943-56254726-5E7B-4505-BB0C-13BFF7D92BB7Q27675820-0A5CE852-0427-41A4-8E99-31977F0CA51FQ28211719-B9B7F659-C449-4A5B-8F1D-D0712B22C9B3Q28282987-7776449B-0DE6-41E0-AAC6-35E68CBB02F9Q28483628-BC91FF3A-0A38-4196-BA07-6F34EE34A48FQ28510160-7D574B27-C2F2-47B6-9387-D35AA6546013Q28581134-DCF193B5-F2F4-4DE0-AF84-9343D866110DQ32069485-C2D9713F-E5D2-4136-AE0D-8738E372F814Q33426119-365BCD49-4DBC-408F-A3B9-812D71D04A9EQ33593937-8E66D903-C6EE-47B3-A61E-1B782E3666C5Q33797995-C0590E3D-50D7-4C8F-853D-9D37061B84B8Q33807807-38A1DA1B-ED50-4B51-98D2-2BCE61E881B1Q33834966-375A7D53-A335-45CA-9C86-FE14169360FFQ33840099-556E65CF-127F-4E15-AA43-07FDC351CED8Q33888123-E75EDA2E-E30F-459B-9246-F5437E3711E4Q33890625-147E8042-84EF-4231-AC89-F8848757ACBBQ33934010-D89E4F98-9BAF-4D61-9DE4-62B59886C987Q33963311-4779ED9F-ECDE-45E3-A8CB-5B73025CAD7DQ33997297-39E5B7D8-F0D8-4AA2-A778-922E9432D1D6Q33997846-538FF673-237A-49A4-90CA-139F91060438Q34076405-FF444E4F-7E79-4F56-9C02-AFFA049480E9Q34325347-5902464E-E369-4A3D-9D61-4F42332B0863Q34360333-359E69AA-073A-48DC-B138-4EB53F2C7335Q34398166-8A79B5C3-31A5-4CC4-944E-364BA3294B1EQ34452108-33D22360-4E0B-4F0D-ADB5-59FEEE5C264FQ34483626-35ECD744-3B23-4461-AD5B-E90F0837ACF1Q34559139-BA6CD623-7889-4B3A-AB1A-7C1BCCC095A9Q34567032-90E9F659-5DAB-4850-B6A9-BF2080C1B524Q34570100-32112C12-7ECD-496B-A1D2-31BE2F6F826BQ34658173-5EB554D8-55FA-4295-BE6E-F3987D159D55
P2860
Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors
description
1995 nî lūn-bûn
@nan
1995 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1995 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1995年の論文
@ja
1995年学术文章
@wuu
1995年学术文章
@zh-cn
1995年学术文章
@zh-hans
1995年学术文章
@zh-my
1995年学术文章
@zh-sg
1995年學術文章
@yue
name
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@ast
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@en
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@nl
type
label
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@ast
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@en
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@nl
prefLabel
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@ast
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@en
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@nl
P2093
P2860
P356
P1476
Wild-type p53 protein undergoe ...... t not in differentiated tumors
@en
P2093
P2860
P304
P356
10.1073/PNAS.92.10.4407
P407
P577
1995-05-01T00:00:00Z